Skip to main content
COVID-19 variant: Early data
29, Dec 2020

COVID-19 variant: Early data

A new variant of the coronavirus that causes COVID-19 has been reported in the UK. This variant was detected by the Covid-19 Genomics UK (COG-UK) consortium

Source: https://www.bmj.com/content/371/bmj.m4857 

 

A simplified overview of early data is available at the following link

https://www.npr.org/sections/goatsandsoda/2020/12/22/948961575/what-we-know-about-the-new-u-k-variant-of-coronavirus-and-what-we-need-to-find-o

 

Key Details: 

  • The variant is called B.1.1.7 or variant under investigation, the year 2020, month 12, variant 01 (VUI 202012/01)
  • The rate of transmission is 71% higher than other variants
  • The first case occurred on September 20, 2020
  • Sequenced in early October 2020
  • The variant has 17 new mutations, 8 in the spike protein which binds to human cells. Mutations have caused amino acid changes and deletions
  • Mutation N201Y in the receptor-binding domain of the spike protein renders the virus more avid for its human receptor, ACE2.
  • The deletion at positions 69/70 affects the performance of some diagnostic PCR assays
  • Current vaccines should be effective against this variant 
  • The variant does not affect the severity of COVID-19
  • Children are more likely to be affected, because the variant is more contagious, and schools have remained open in some areas
  • Several countries have begun to see cases with this variant

 

Source: https://www.bmj.com/content/371/bmj.m4944 

 

Immunocompromized patients

  • Some mutations seen in the variant may have occurred in immunocompromised patients

Source: https://www.medrxiv.org/content/10.1101/2020.12.05.20241927v2.supplementary-material 

 

Mathematical modeling by a group of researchers predicts a higher transmission rate than pre-existing variants of SARS-CoV-2, without clear evidence of altered disease severity. These models project increased spread unless vaccination roll-outs are accelerated, and school-based transmission is reduced. 

Source: https://cmmid.github.io/topics/covid19/uk-novel-variant.html 

 

About

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to

  • - Assess disease risk for several immunological disorders.
  • - Predict the success of a drug for a specific patient.
  • - Develop dosing recommendations for new immunological drugs.

Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.

Contact